摘要
多发性骨髓瘤（MM）为浆细胞恶性肿瘤,以溶骨性破坏、免疫缺陷、肾脏损害为特点.近年来,MM的治疗取得了长足进展,尤其是泛素蛋白酶体系统（UPS）抑制剂硼替佐米的应用为MM患者带来希望,但部分MM患者在治疗过程中出现硼替佐米耐药.笔者拟就MM概述、UPS的组成与蛋白酶体的结构、硼替佐米用于MM的疗效等方面,对MM硼替佐米的耐药机制,如核因子（NF）-κB信号转导途径、蛋白酶体β5亚基（PSMB5）、黏后蛋白1C末端亚单位（MUC1-C）、凋亡途径及热休克蛋白（HSP）等进行综述.
Multiple myeloma （MM） is a plasma cell malignancy,with osteolytic destruction,immunodeficiency,kidney damage.In recent years,great progress has been made in the treatment of MM,especially the application of bortezomib（one of proteasome inhibitors） brings hope for MM patients,while some MM patients develop bortezomib resistance in the course of treatment.This article reviews literatures on brief introduction of MM,structure of the proteasome,curative effects of bortezomib in MM,and mechanism of drug resistance with bortezomib in MM,such as nuclear factor （NF）-κB,proteasome beta 5 subunit （PMSB5）,mucin 1 C-terminal subunit （MUC1-C）,apoptosis pathway and heat shock protein （HSP）,et al.
出处
《国际输血及血液学杂志》
CAS
2015年第6期505-508,共4页
International Journal of Blood Transfusion and Hematology
基金
河北省自然科学基金资助项目（H2013406112）
